Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Muramyl dipeptide derivative and its clinical application].

E Tsubura

    Kekkaku : [Tuberculosis]
    |November 1, 1989
    PubMed
    Summary

    Muroctasin, a synthetic muramyl dipeptide derivative, effectively restores white blood cell counts in lung cancer patients undergoing chemotherapy. This treatment helps combat chemotherapy-induced leukopenia and may prevent infections in compromised hosts.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Filter cigarette smoking and lung cancer risk; a hospital-based case--control study in Japan.

    British journal of cancer·2004
    Same author

    [Comparison of the newly developed MB redox system with mycobacteria growth indicator tube (MGIT) and 2% Ogawa egg media for recovery of mycobacteria in clinical specimens].

    Kekkaku : [Tuberculosis]·1999
    Same author

    [The studies on tuberculosis present research ideas for medicine].

    Kekkaku : [Tuberculosis]·1998
    Same author

    [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].

    Gan to kagaku ryoho. Cancer & chemotherapy·1998
    Same author

    [A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].

    Gan to kagaku ryoho. Cancer & chemotherapy·1998
    Same author

    [Report of questionnaire about enterohemorrhagic Escherichia coli cases caused in the area including Sakai City in 1996].

    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases·1998

    Area of Science:

    • Immunology
    • Pharmacology
    • Oncology

    Context:

    • Bacterial cell wall components, like muramyl dipeptide (MDP), possess immune-modulating properties.
    • Synthetic MDP derivatives offer therapeutic potential with improved safety profiles.
    • Leukopenia is a common and serious side effect of cancer chemotherapy.

    Purpose:

    • To evaluate the clinical efficacy and safety of muroctasin (MDP-Lys (L 18)) in restoring white blood cell counts in cancer patients experiencing chemotherapy-induced leukopenia.
    • To determine the optimal dosage and administration of muroctasin for treating leukopenia.

    Summary:

    • Muroctasin demonstrated significant restorative activity against leukopenia in lung cancer patients post-chemotherapy.
    • Phase II and III clinical studies in Japan established an optimal daily dosage of 200 micrograms, administered subcutaneously six times.
    • The proposed mechanism involves muroctasin stimulating macrophages to produce colony-stimulating factors (CSF), thereby increasing granulocyte production.

    Impact:

    • Muroctasin offers a novel therapeutic approach to manage chemotherapy-induced leukopenia, potentially improving patient tolerance to cancer treatment.
    • This MDP derivative may reduce the incidence of infections in neutropenic cancer patients, enhancing overall outcomes.
    • The successful clinical application of muroctasin represents a significant advancement in supportive care for cancer patients.

    Related Experiment Videos